Ying Luo
CIK: 0001959160
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (66.7%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (33.3%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
GYRE
GYRE THERAPEUTICS, INC.
DirectorOfficer
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jun 8, 2026GYRE
GYRE THERAPEUTICS, INC.
Award(A)DirectStock Option (Right to Buy)
120K shares- - May 6, 2026GYRE
GYRE THERAPEUTICS, INC.
Sale(S)Indirect10.1K shares at avg. $8.04$81K - May 5, 2026GYRE
GYRE THERAPEUTICS, INC.
Sale(S)Indirect179 shares at avg. $8.01$1K
1-3 of 3 transactions
About Luo Ying
Luo Ying (SEC CIK 0001959160) files insider reports with the SEC as Chief Executive Officer of GYRE THERAPEUTICS, INC. (GYRE).
Signal8 holds 3 ownership filings by Luo Ying (1 Form 3, 2 Form 4), filed between May 7, 2026 and Jun 10, 2026. Those filings report 3 transactions, from May 5, 2026 to Jun 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Luo Ying's filings is in SAN DIEGO, CA.
Recent filings by Luo Ying
Other insiders filing for GYRE THERAPEUTICS, INC. (GYRE)
- Weston Claire, Director
- Kirkby Maxwell, Director
- Ye Weiguo, Chief Operating Officer
- Bergmann Joshua Benjamin, GC and Corporate Secretary
- Zhang Ping, Director
- Wang Jialiang (NMN), EVP, General Manager